aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Preclinical lung-model findings showed reduced collagen content and lung-scarring scores compared with nintedanib as a control.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
aTyr Pharma (ATYR) announced a Journal of Biological Chemistry publication demonstrating anti-fibrotic effects of ATYR0101 in preclinical research.
ATYR0101 targets LTBP-1, a protein in the material surrounding cells, to trigger programmed death of myofibroblasts, cells involved in tissue scarring. In a bleomycin-induced lung fibrosis model, ATYR0101 reduced collagen content and Ashcroft score, a measure of lung scarring, compared with nintedanib as a control. The candidate has also demonstrated anti-fibrotic effects in lung and kidney fibrosis models. It is undergoing studies needed to support an investigational new drug application; aTyr expects to advance it into clinical testing in 2027.
Positive
- Minor pointATYR0101 reduced collagen content and Ashcroft score versus nintedanib in a bleomycin-induced lung fibrosis model.
- Minor pointATYR0101 selectively triggered programmed myofibroblast death by targeting LTBP-1.
- Minor pointATYR0101 demonstrated anti-fibrotic effects in kidney fibrosis models.
- Minor point. Forward-looking: it has not happened yet and may not happen.aTyr expects ATYR0101 to enter clinical testing in 2027; supporting application studies are underway.
Negative
- Minor pointATYR0101-induced myofibroblast death was dependent on active TGF-β, a protein involved in fibrosis.
Details
Market move: ATYR -6.42% vs previous close. ATYR0101 preclinical data
On Oct 13, the day this news came out, the latest delayed price for ATYR is 6.42% below the previous close. Our momentum scanner has recorded 14 alerts for this stock so far that day. The latest delayed price is $0.20. Relative volume is above average at 1.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Expected clinic advancement
- 2027
- ATYR0101; company expects advancement after IND-enabling studies
Key Terms
ind-enabling regulatory
apoptosis medical
transforming growth factor beta medical
tRNA synthetase technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.
ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.
SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. The publication, entitled, “Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to Abrogate Tissue Fibrosis,” is available on the journal’s website and at: https://www.jbc.org/article/S0021-9258(26)02458-0/fulltext.
ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce myofibroblast apoptosis.
“Fibrosis remains a major global health challenge across multiple organ and tissue systems with limited therapies that only slow disease progression,” said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr Pharma. “This publication highlights the novel mechanism by which ATYR0101 disrupts fibrosis through a unique molecular program that facilitates a transition towards a restorative phenotype thus fundamentally altering the underlying fibrotic cellular landscape. These findings suggest that ATYR0101 does not merely stop disease progression but may also facilitate a reversal of fibrotic pathology, providing a differentiated approach to current anti-fibrotic therapies in conditions such as idiopathic pulmonary fibrosis, where more effective treatment options are greatly needed.”
The publication describes the mechanism by which ATYR0101 selectively triggers apoptosis in myofibroblasts by targeting LTBP-1 on the extracellular matrix, with ATY0101 induced myofibroblast apoptosis shown to be dependent on active transforming growth factor beta (TGF-β), a central player in the pathogenesis of fibrotic diseases. Furthermore, the pharmacologic activity of ATYR0101 was demonstrated in an in vivo bleomycin lung model of fibrosis, where ATYR0101 showed a significant reduction in both collagen content and Ashcroft score leading to a marked decline in pulmonary fibrosis compared to the use of nintedanib, a known anti-fibrotic, as a control.
About ATYR0101
ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce myofibroblast apoptosis. ATYR0101 interacts with LTBP-1 through a unique way that presents a differentiated approach to targeting fibrosis. ATYR0101 has demonstrated anti-fibrotic effects in models of lung and kidney fibrosis suggesting it may have broad therapeutic potential in multiple fibrotic diseases. ATYR0101 is currently undergoing IND-enabling studies.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipate," “believes,” “can,” “could,” “designed,” “expects,” “intends,” “may,” “plans,” “potential,” “upcoming,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the potential therapeutic benefits and applications of ATYR0101, including the potential for ATYR0101 to provide a differentiated approach to current anti-fibrotic therapies in conditions such as idiopathic pulmonary fibrosis; timelines, plans and expected results with respect to certain research and development activities and development goals, including IND-enabling studies and our expectation that ATYR0101 will be advanced into the clinic in 2027. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risks inherent in studies of potential medical therapies, the risk that we or future partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that future collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: |
| Ashlee Dunston |
| Investor Relations and Public Affairs adunston@atyrpharma.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did aTyr Pharma's ATYR0101 publication show in the lung fibrosis model?
ATYR0101 reduced collagen content and Ashcroft score compared with nintedanib as a control in a bleomycin-induced lung fibrosis model. These were preclinical findings, not results from treatment of patients.
When does aTyr Pharma expect ATYR0101 to enter clinical testing?
aTyr expects to advance ATYR0101 into clinical testing in 2027. The candidate is currently undergoing studies needed to support an investigational new drug application.
What does ATYR0101's effect on myofibroblasts depend on?
ATYR0101-induced programmed death of myofibroblasts was shown to depend on active transforming growth factor beta (TGF-β). This protein plays a role in the development of fibrotic diseases.